Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeurogesX peripheral neuropathic pain drug accepted for review
NGX-4010 is a dermal patch that has been studied successfully in three Phase III clinical trials in patients suffering from peripheral neuropathic pain conditions. Two Phase III clinical
NGX-4010 is a dermal patch that has been studied successfully in three Phase III clinical trials in patients suffering from peripheral neuropathic pain conditions. Two Phase III clinical
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) proposal includes amending the summaries of product characteristics (SmPCs) for all approved ESAs to stipulate a
Fred Mermelstein, president and founder, said: “Upon approval, PMI-150 will be the only intranasal ketamine product offering physicians and patients a non-opioid alternative for treatment of moderate to
Trevor Hallam, executive vice president of R&D for Palatin, said: “We are pleased with the overall data from this exploratory trial. The efficacy response was consistent and robust
Zyflo CR and Zyflo (zileuton tablets) are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of
Pafuramidine is among the first drugs to be considered for fast track status under new and more stringent State Food and Drug Administration (SFDA) rules recently introduced in
PS433540 is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. The study showed that all
Symphony GenIsis was formed in April 2006 by Symphony Capital Partners and capitalized with $75 million, to fund development of three of Isis’ drugs. As part of that
The study demonstrated that incyclinide was well-tolerated, with most adverse events being mild or moderate. However, the patients who were administered incyclinide did not demonstrate a greater reduction
Dr Reddy’s will market the product under a new brand name through its new dermatology division. The agreement grants Dr Reddy’s exclusivity in the US, for Sebclair and